ImprimisRx has agreed to a product supply agreement with iOR Partners. Under the agreement, ImprimisRx will provide a variety of formulations needed for in-office surgeries, including the MKO Melt® and various injectable and topical products. iOR Partners focuses on the field of office-based cataract surgery, which is a surgical or invasive procedure performed by a licensed physician in a location other than a hospital or ambulatory surgery center that utilizes minimal to moderate anesthetics. By keeping their clinic and surgery center in one place, doctors can see more patients, employ the same staff for clinic and surgery, improve productivity, and lower patient anxiety by having procedures performed in a familiar environment. iOR is expected to have 75 office-based cataract surgery suites by the end of next year, accounting for more than 45,000 surgical procedures annually.
“iOR Partners has an exciting business model and we are thrilled to partner with them as they help ophthalmologists make it easier to provide high-quality care to their patients. In-office surgery is likely where the ophthalmic surgery market is headed, so we’re pleased to provide iOR with the pharmaceutical formulations needed to continue the impressive progress they’re making as they help lead our industry forward,” John Saharek, President of ImprimisRx, said.
“ImprimisRx is a trusted provider within the ophthalmic community offering a unique suite of formulations not available commercially, and are a natural fit for ophthalmologists looking to provide a more personalized and comfortable patient experience. Both companies are passionate about helping doctors to improve the patient experience, so we are excited to have ImprimisRx working with us going forward,” Tony Burns, Founder and Partner of iOR Partners, said.